Abstract
Objective
To analyze and explore the risk factors of skip lateral cervical lymph node metastasis (SLLNM) in papillary thyroid carcinoma (PTC).
Methods
PubMed, Web of Science, Embase, Cochrane, Wanfang, China National Knowledge Infrastructure, and China Science and Technology Journal databases, updated to April 4, 2021, were systematically searched for literature on the risk factors of SLLNM in PTC. The meta-analysis was completed using Stata 15.0 software after quality evaluation. The odds ratio (OR) and 95% confidence interval (CI) of each variable were calculated using fixed or random-effects models, and the publication bias was evaluated by the Egger’s test.
Results
A total of 28 studies with 10,682 cases were included in our meta-analysis; 1592 (14.90%) cases were positive for SLLNM. The meta-analysis showed that female sex (OR = 1.16, 95% CI = 1.02–1.31, P = 0.021), age ≥45 (OR = 1.60, 95% CI = 1.19–2.15, P = 0.002), tumor diameter ≤10 mm (OR = 2.23, 95% CI = 1.62–3.06, P < 0.001), and upper location of tumor (OR = 3.60, 95% CI = 2.65–4.89, P < 0.001) were risk factors for SLLNM in PTC patients. Hashimoto’s thyroiditis (OR = 1.02, 95% CI = 0.88–1.19, P = 0.777), multifocality (OR = 0.98, 95% CI = 0.75–1.28, P = 0.873), bilateral tumors (OR = 0.92, 95% CI = 0.70–1.19, P = 0.515), extrathyroidal extensions (OR = 1.07, 95% CI = 0.83–1.39, P = 0.598), and capsular invasion (OR = 0.93, 95% CI = 0.65–1.31, P = 0.660) were not closely related to SLLNM risk.
Conclusion
This study confirmed significant associations between SLLNM and female sex, age ≥45, tumor diameter ≤10 mm, and upper location of the tumor.
Similar content being viewed by others
Data availability
The data sets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.
References
Y.J. Jo, H.R. Choi, S.H. Park, Y.J. Jeong, Extent of thyroid surgery for clinically node-negative papillary thyroid carcinoma with confirmed nodal metastases after prophylactic central neck dissection: a 15-year experience in a single center. Ann. Surg. Treat. Res. 99, 197–204 (2020)
Y.K. So, M.J. Kim, S. Kim, Y.I. Son, Lateral lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis for prevalence, risk factors, and location. Int J. Surg. 50, 94–103 (2018)
H. Kim, T.H. Kim, J.H. Choe, J.H. Kim, J.S. Kim et al. Patterns of initial recurrence in completely resected papillary thyroid carcinoma. Thyroid 27, 908–914 (2017)
S. Noguchi, A. Noguchi, N. Murakami, Papillary carcinoma of the thyroid. I. Developing pattern of metastasis. Cancer 26, 1053–1060 (1970)
B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1–133 (2016)
F. Pacini, M.G. Castagna, L. Brilli, G. Pentheroudakis, E.G.W. Group, Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl 5), S214–S219 (2010)
M. Song, Z. Huang, S. Wang, J. Huang, H. Shi et al. Predictive factors of lateral lymph node metastasis in conventional papillary thyroid carcinoma. Gland Surg. 9, 1000–1007 (2020)
Y. Huang, Y. Yin, W. Zhou, Risk factors for central and lateral lymph node metastases in patients with papillary thyroid micro-carcinoma: retrospective analysis on 484 cases. Front Endocrinol. 12, 640565 (2021)
M.A. Adam, J. Pura, P. Goffredo, M.A. Dinan, S.D. Reed et al. Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J. Clin. Oncol. 33, 2370–2375 (2015)
J. Hou, Y. Zhang, Y. Fan, B. Wu, Risk factors of skip lateral lymph node metastasis in papillary thyroid carcinoma. Eur. Arch. Otorhinolaryngol. 278, 493–498 (2021)
D. Hu, H. Lin, X. Zeng, T. Wang, J. Deng et al. Risk factors for and prediction model of skip metastasis to lateral lymph nodes in papillary thyroid carcinoma. World J. Surg. 44, 1498–1505 (2020)
A. Attard, N.C. Paladino, A.I. Lo Monte, N. Falco, G. Melfa et al. Skip metastases to lateral cervical lymph nodes in differentiated thyroid cancer: a systematic review. BMC Surg. 18, 112 (2019)
A. Machens, H.J. Holzhausen, H. Dralle, Skip metastases in thyroid cancer leaping the central lymph node compartment. Arch. Surg. 139, 43–45 (2004)
T. Li, Z. Jiang, M. Lu, S. Zou, M. Wu et al. Computer-aided diagnosis system of thyroid nodules ultrasonography: Diagnostic performance difference between computer-aided diagnosis and 111 radiologists. Medicines 99, e20634 (2020)
J. Liang, X. Huang, H. Hu, Y. Liu, Q. Zhou et al. Predicting malignancy in thyroid nodules: radiomics score versus 2017 American College of Radiology Thyroid Imaging, Reporting and Data System. Thyroid 28, 1024–1033 (2018)
J. Ding, W. Wu, J. Fang, J. Zhao, L. Jiang, Male sex is associated with aggressive behaviour and poor prognosis in Chinese papillary thyroid carcinoma. Sci. Rep. 10, 4141 (2020)
C. Sui, Q. He, R. Du, D. Zhang, F. Li et al. Lymph node characteristics of 6279 N1 differentiated thyroid cancer patients. Endocr. Connect. 9, 201–210 (2020)
M. Kim, H.K. Kim, H.I. Kim, E.H. Kim, M.J. Jeon et al. Modification of the eight-edition tumor-node-metastasis staging system with N1b for papillary thyroid carcinoma: a multi-institutional cohort study. Oral. Oncol. 86, 48–52 (2018)
P.E. Voutilainen, M.M. Multanen, A.K. Leppaniemi, C.H. Haglund, R.K. Haapiainen et al. Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age. Thyroid 11, 953–957 (2001)
Z. Xin, X. Shuai, Y. Yue, C. Guang, Related factors on skip metastasis of neck lymph node in papillary thyroid carcinoma. Chin. J. Surg. 55, 599–602 (2017)
R. Sun, H. Zhang, K. Liu, J. Fan, G. Li et al. Clinicopathologic predictive factors of cervical lymph node metastasis in differentiated thyroid cancer. Acta Otorrinolaringol. Esp. 69, 149–155 (2018)
H. Zhao, T. Huang, H. Li, Risk factors for skip metastasis and lateral lymph node metastasis of papillary thyroid cancer. Surgery 166, 55–60 (2019)
S. Ozden, B. Comcali, H. Atas, S. Er, M. Tez et al. A diagnostic dilemma: skip metastasis in papillary thyroid cancer. Am. Surg. 86, 245–249 (2020)
J.-W. Feng, A.-C. Qin, J. Ye, H. Pan, Y. Jiang et al. Predictive factors for lateral lymph node metastasis and skip metastasis in papillary thyroid carcinoma. Endocr. Pathol. 31, 67–76 (2020)
C.I. Lee, O. Kutlu, Z.F. Khan, O. Picado, J.I. Lew, Margin positivity and survival in papillary thyroid microcarcinoma: a national cancer database analysis. J. Am. Coll. Surg. 233, 537–544 (2021)
K. Back, J.S. Kim, J.H. Kim, J.H. Choe, Superior located papillary thyroid microcarcinoma is a risk factor for lateral lymph node metastasis. Ann. Surg. Oncol. 26, 3992–4001 (2019)
D. Xiang, L. Xie, Y. Xu, Z. Li, Y. Hong et al. Papillary thyroid microcarcinomas located at the middle part of the middle third of the thyroid gland correlates with the presence of neck metastasis. Surgery 157, 526–533 (2015)
Y. Dou, D. Hu, Y. Chen, W. Xiong, Q. Xiao et al. PTC located in the upper pole is more prone to lateral lymph node metastasis and skip metastasis. World J. Surg. Oncol. 18, 188 (2020)
I. Likhterov, L.L. Reis, M.L. Urken, Central compartment management in patients with papillary thyroid cancer presenting with metastatic disease to the lateral neck: Anatomic pathways of lymphatic spread. Head. Neck 39, 853–859 (2017)
F.I. Moulana, A.A.H. Priyani, M.V.C. de Silva, R.S. Dassanayake, BRAF-oncogene-induced senescence and the role of thyroid-stimulating hormone signaling in the progression of papillary thyroid carcinoma. Horm. Cancer 9, 1–11 (2018)
J. Mao, Q. Zhang, H. Zhang, K. Zheng, R. Wang et al. Risk factors for lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis. Front Endocrinol. 11, 265 (2020)
W.X. Jin, Y.X. Jin, D.R. Ye, Z.C. Zheng, Y.H. Sun et al. Predictive factors of skip metastasis in papillary thyroid cancer. Med. Sci. Monit. 24, 2744–2749 (2018)
S. Jingjing, D. Jinwang, P. You, Z. Yu, P. Gang, Clinical risk factors analysis and model prediction of skip lateral cervical lymph node metastasis in papillary thyroid microcarcinoma. Chin. J. Exp. Surg. 37, 2289–2291 (2020)
J.H. Park, Y.S. Lee, B.W. Kim, H.S. Chang, C.S. Park, Skip lateral neck node metastases in papillary thyroid carcinoma. World J. Surg. 36, 743–747 (2012)
W. Wendong, G. Jialei, Z. Weihui, W. Peng, Clinical study of lymphatic drainage pathways in central and lateral neck of patients with papillary thyroid carcinoma. Chin. J. Crit. Care Med. (Electron. Ed.) 12, 158–162 (2019)
Z. Huang, M. Song, S. Wang, J. Huang, H. Shi et al. Preoperative serum thyroglobulin is a risk factor of skip metastasis in papillary thyroid carcinoma. Ann. Transl. Med. 8, 389 (2020)
Author information
Authors and Affiliations
Contributions
Lingqian Zhao and Fan Wu contributed equally to this work. Dingcun Luo had full access to all of the data in the manuscript and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript. Concept and design: all authors. Acquisition, analysis, or interpretation of data: all authors. Drafting of the manuscript: Lingqian Zhao and Fan Wu. Critical revision of the manuscript for important intellectual content: Lingqian Zhao, Fan Wu and Dingcun Luo. Statistical analysis: Lingqian Zhao and Fan Wu. Supervision: Yu Zhang and Dingcun Luo.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Ethics approval
Not applicable.
Informed consent
Informed consent is not required for such an article.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhao, L., Wu, F., Zhou, T. et al. Risk factors of skip lateral cervical lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis. Endocrine 75, 351–359 (2022). https://doi.org/10.1007/s12020-021-02967-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-021-02967-9